Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
08.09.2022 Save the date: GBG-Jahrestreffen 2023
Das GBG-Jahrestreffen 2023 findet am 2.&3. März 2023 in Frankfurt statt.
02.09.2022 August 2022 : Neoadjuvant durvalumab improves survival in early triple-negative breast cancer despite a modest pCR increase – follow-up data from GeparNuevo trial
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
03.08.2022 GBG-Research at EMSO 2022
We are proud to present our research at ESMO Congress 2022 in Paris.
31.07.2022 July 2022: HER2-positive breast cancer patients with brain metastases have the best prognosis compared to other tumor subtypes
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
14.07.2022 Eight-year data from APHINITY study presented
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
30.06.2022 June 2022: Pregnancy does not impact the effectiveness of chemotherapy for breast cancer.
We are pleased to inform you that outcome of pregnant breast cancer patients treated with chemotherapy versus non-pregnant controls has been published in European Journal of Cancer
03.06.2022 WIR ZIEHEN UM!
Bitte beachten Sie unsere neue Anschrift ab dem 18. Juli 2022.
31.05.2022 May 2022: Effect of denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy for primary breast cancer – results from GeparX trial
We are pleased to inform you that primary results from GeparX trial have been published in JAMA Oncology.
24.05.2022 Ovarian Toxicity Assessment
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
23.05.2022 Ergebnisse zur Brustkrebs in der Schwangerschaft
Neue Daten zum Überleben von Brustkrebspatientinnen mit Chemotherapie während der Schwangerschaft
12.05.2022 GBG Research at ASCO 2022
We are happy to present our research at the ASCO Annual meeting June 2022.
30.04.2022 April 2022: Adjuvant pertuzumab significantly improved invasive disease-free survival for HER2-positive, N-positive early breast cancer in the APHINITY trial
We are pleased to inform you that a STEPP analysis of the updated data from the APHINITY trial has been published in European Journal of Cancer
22.04.2022 ESMO Breast Cancer Meeting
GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.
05.04.2022 2022 ESMO Breast Cancer Award for Sibylle Loibl
ESMO has announced that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
31.03.2022 March 2022: Long-term outcomes from the BrighTNess trial support inclusion of carboplatin in neoadjuvant chemotherapy for early-stage TNBC.
We are pleased to inform you that 4-year follow-up data from the BrighTNess trial has been published in Annals of Oncology.
22.03.2022 Patienten für Online-Studie gesucht
„Ich habe / hatte Krebs“ Welches Bild haben Betroffene von ihrer Brustkrebserkrankung? Teilnehmer*innen für wissenschaftliche Online-Studie gesucht
11.03.2022 GBG Jahrestreffen 2022
Vielen Dank für Ihre Teilnahme am GBG-Jahrestreffen 2022. Sie finden die Vorträge hier zum Nachlesen auf unserer Website.
28.02.2022 February 2022: Effects of capecitabine as part of neo-/adjuvant chemotherapy
We are pleased to inform you that a meta-analysis of capecitabine effect as part of neo-/adjuvant chemotherapy including 15,993 patients from 13 randomized trials has been published in European Journal of Cancer.
15.02.2022 Save the date: AGO Mamma - State of the Art
Das AGO Mammakarzinom - State of the Art Meeting findet am 19. März 2022 online statt.
31.01.2022 January 2022: pCR in the breast and axillary lymph nodes correlates with iDFS – results from GeparOcto trial
We are pleased to inform you that an exploratory analysis of the randomized phase III GrparOcto trial has been published in Cancer
